Correlation Between Molecular Partners and BioNTech
Can any of the company-specific risk be diversified away by investing in both Molecular Partners and BioNTech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and BioNTech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Molecular Partners AG and BioNTech SE, you can compare the effects of market volatilities on Molecular Partners and BioNTech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of BioNTech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and BioNTech.
Diversification Opportunities for Molecular Partners and BioNTech
-0.17 | Correlation Coefficient |
Good diversification
The 3 months correlation between Molecular and BioNTech is -0.17. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and BioNTech SE in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioNTech SE and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with BioNTech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioNTech SE has no effect on the direction of Molecular Partners i.e., Molecular Partners and BioNTech go up and down completely randomly.
Pair Corralation between Molecular Partners and BioNTech
Given the investment horizon of 90 days Molecular Partners AG is expected to generate 1.64 times more return on investment than BioNTech. However, Molecular Partners is 1.64 times more volatile than BioNTech SE. It trades about 0.03 of its potential returns per unit of risk. BioNTech SE is currently generating about 0.03 per unit of risk. If you would invest 531.00 in Molecular Partners AG on October 25, 2024 and sell it today you would earn a total of 2.00 from holding Molecular Partners AG or generate 0.38% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Molecular Partners AG vs. BioNTech SE
Performance |
| Timeline |
| Molecular Partners |
| BioNTech SE |
Molecular Partners and BioNTech Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Molecular Partners and BioNTech
The main advantage of trading using opposite Molecular Partners and BioNTech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, BioNTech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will offset losses from the drop in BioNTech's long position.| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
| BioNTech vs. Novavax | BioNTech vs. Ginkgo Bioworks Holdings | BioNTech vs. Crispr Therapeutics AG | BioNTech vs. Ocean Biomedical |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |